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Introduction: Intravenous augmentation therapy with purified intravenous alpha-1 antitrypsin 
replaces the deficient protein and is the only currently approved treatment for alpha-1 antitrypsin 
deficiency (AATD) related lung disease. While augmentation therapy has been available for 
more than 20 years, there are a limited number of studies evaluating the effect of augmentation 
on lung function.
Material and methods: We examined the decline in forced expiratory volume in one second 
(FEV1) in patients enrolled in the Alpha-1 Foundation DNA and Tissue Bank in relation to 
the use or not of alpha-1 antitrypsin augmentation therapy. For the purpose of our analysis we 
included 164 patients with AATD and PI ZZ genotype.
Results: Mean age of the patients was 60 years, 52% were females, 94% were white and 78% 
ex-smokers. The mean FEV1 at baseline was 1.7 L and the mean FEV1 % of predicted was 51.3%. 
The mean follow-up time was 41.7 months. A total of 124 (76%) patients received augmentation 
therapy (augmented group) while 40 patients (24%) did not received it (non-augmented group). 
When adjusted by age at baseline, sex, smoking status, baseline FEV1 % of predicted, the mean overall 
change in FEV1 was 47.6 mL/year, favoring the augmented group (∆FEV1 10.6 ± 21.4 mL/year) 
in comparison with the non-augmented group (∆FEV1 −36.96 ± 12.1 mL/year) (P = 0.05). 
Beneficial ∆FEV1 were observed in ex-smokers and the group with initial FEV1 % of predicted 
of 50%. No differences were observed in mortality.
Conclusions: In conclusion, augmentation therapy improves lung function in subjects with 
AATD when adjusted by age, gender, smoking status and baseline FEV1 % of predicted. The 
beneficial effects were noted in ex-smoker subjects with FEV1 below 50% of predicted.
Keywords: alpha-1 antitrypsin deficiency, augmentation therapy, forced expiratory volume 
in one second
Introduction
Alpha-1 antitrypsin deficiency (AATD) is an autosomal codominant inherited condition 
characterized by low levels of alpha-1 antitrypsin in serum and tissues. This protein, 
primarily produced in the liver, is the most prevalent protease inhibitor in serum and 
its main function is to inhibit neutrophil elastase, a proteolytic enzyme capable of 
destroying alveolar structures.1–3 The imbalance between proteases and antiproteases 
leads to alveolar destruction that in turn results in a rapid decline of the forced 
expiratory volume in one second (FEV1) and the development of emphysema at an 
early age.4 Factors associated with a more rapid FEV1 decline include male gender, 
older age (specially after 50 years), low BMI, current smoking status, presence of 
bronchodilator response, frequent respiratory exacerbations and mid-range FEV1 % of International Journal of COPD 2009:4 444
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predicted (actual percentage varied according to the studies 
from 35% to 80%).5–14
Augmentation therapy with purified intravenous alpha-1 
antitrypsin replaces the deficient protein and is the only currently 
approved treatment for AATD. Few observational studies have 
demonstrated a beneficial effect of augmentation therapy 
with alpha-1 antitrypsin, in reducing the rapid decline in lung 
function seen in patients with this condition.5,15,16 However, 
a randomized study in patients with moderate to severe 
emphysema demonstrated no changes in the annual FEV1 
decline in the placebo versus the treatment arm.17
We sought to examine the effect of alpha-1 antitrypsin 
augmentation therapy on FEV1 decline, in AATD patients 
enrolled in the Alpha-1 Foundation DNA and Tissue 
Bank study.
Material and methods
The Alpha-1 Foundation DNA and Tissue Bank collected, 
from across the United States, medical information and 
human tissue of individuals with AATD, immediate relatives 
of individuals with AATD and subjects without the disease 
who were interested in the project.
The Alpha-1 Foundation DNA and Tissue Bank project 
is sponsored by the Alpha-1 Foundation and is physically 
located at the University of Florida College of Medicine, 
Gainesville, FL, USA. The Alpha-1 Foundation DNA and 
Tissue Bank protocol and analysis of the data presented 
in this article were approved by the University of Florida 
Institutional Review Board.
Upon enrollment, individuals signed an informed consent 
and completed a registration form as well as an extensive 
medical questionnaire. The answers written in the introductory 
questionnaire were reviewed in detail and corroborated during 
an initial phone interview with the study participant. If the 
individuals indicated that they agreed to be contacted, they 
were called annually to update their medical information.
FEV1 measured in liters and percentage of predicted were 
recorded at the time of the initial medical questionnaire and 
during annual phone interviews. For the purpose of the current 
analysis, patients were included if they had a proven PI ZZ 
genotype (by Taqman allelic discrimination) and at least two 
recorded postbronchodilator FEV1 measurements, 6 months 
apart or more. Patients not meeting the inclusion criteria or 
who underwent lung or liver transplant were excluded from 
the analysis. Great attention was put to assure high quality 
spirometric measurements following American Thoracic 
Society standards. Spirometry results that questioned the 
patient’s effort during the test were not recorded.
All the recorded FEV1 measurements were used to 
estimate the change in FEV1 (∆FEV1). A change in FEV1 
(∆FEV1) is defined as the initial FEV1 in L/m minus the 
FEV1 obtained by random effects model. A positive ∆FEV1 
represents an increase in FEV1 and a negative ∆FEV1 corre-
sponds to a decrease in FEV1. We favored the use of ∆FEV1 
instead of decline in FEV1 as we believe that a positive or 
negative ∆FEV1 is easier to understand than a positive or 
negative rate of decline in FEV1 or a positive or negative 
FEV1 slope (5). The overall change in FEV1 was defined 
as the difference in ∆FEV1 between the augmented and the 
non-augmented group.
Patients were divided into 2 groups: 1) “augmented” 
(patients who were receiving augmentation therapy at time 
of the inclusion in the study), 2) “nonaugmented“(patients 
who were not receiving augmentation therapy at the time of 
the inclusion in the study).
The decision to treat or not treat AATD patients with 
augmentation therapy was made by the patients’ physicians. 
The Alpha-1 Foundation DNA and Tissue Bank did not 
intervene in any way in the treatment plan of patients that 
participated in this study.
Patients were stratified in different groups according 
to the initial FEV1 percentage of predicted. One stratifica-
tion divided the patients in 3 groups (FEV1  30%, 30% 
to 65% and 65% of predicted) using the most commonly 
described cut-off in the literature.15,16 In order to increase 
the numbers of patients in each group and provide more 
reliable conclusions, patients were also divided in 2 groups 
(FEV1  50% or 50% of predicted).5 In addition we studied 
the group of patients with an initial FEV1 of 35% to 49% 
of predicted, because this group was the one that benefit the 
most from augmentation therapy in the Alpha-1-Antitrypsin 
Deficiency Registry Study Group.5
Patients were also classified according to the smoking 
status. Current smoker was defined as the individual who was 
smoking at the time of the inclusion in the study. Ex-smoker 
was defined as a person who had not smoked for at least 
3 months. Nonsmoker was defined as a subject who smoked 
less than 20 packs in his/her lifetime.
Statistical analysis
The decline in post-bronchodilator FEV1 per year was 
estimated separately for each group by random effects models, 
which included FEV1 as the outcome variable, FEV1 (% of 
predicted value) and age at baseline, sex and smoking status 
as fixed parameters, and the individual patients and follow-up 
time as random effects parameters. The estimated ∆FEV1 was International Journal of COPD 2009:4 445
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compared between the augmented and the non-augmented 
groups, and the P-value was calculated using Z-test. The 
analysis was repeated after including 26 patients in whom the 
smoking history was initially missing. This information was 
retrieved from an earlier version of the study database. T-test 
and Chi-square test or Fisher’s exact test were used to compare 
continuous and categorical variables, respectively. The analysis 
of mortality at 5 years was performed with the use of logistic 
regression with age, gender, baseline FEV1, presence of COPD 
and smoking status as covariates. Values are expressed as 
mean (± standard error of the mean). A P-value  0.05 was 
considered significant. All calculations were performed with 
the use of SAS software (version 6.10; SAS Institute Cary, NC, 
USA). Figures were created with Prism 5 for Windows version 
5.00 (GraphPad Software, Inc., La Jolla, CA, USA).
Results
Baseline characteristics
Out of a total of 2,268 patients included in the Alpha-1 
Foundation DNA and Tissue bank from January 2001 to 
April 2009, 777 patients had a Pi ZZ genotype. Of the patients 
with Pi ZZ genotype only 215 had 2 or more measurements 
of FEV1 at least 6 months apart. We excluded 17 patients 
who had lung (n = 15) or liver transplantation (n = 2), and 
8 patients who did not have the initial FEV1 % of predicted, 
which was used as a baseline covariate in the model. 
Twenty-six patients had missing smoking history. For the 
purpose of our analysis we included 164 patients, in whom 
all the variables included in the random effects model were 
available (Figure 1).
The mean age at the time of inclusion in the study was 
60 (±0.73) years. The mean age at the time of diagnosis of 
AATD was 45.9 (±0.72) years. The majority of patients 
(94%) were white (the rest did not report race) and 51.8% 
were females. The greater part of patients were ex-smokers 
(n = 128, 78%). Nonsmokers and current smokers constituted 
20.8% (n = 34) and 1.2% (n = 2) of the individuals, 
respectively. Of the patients that smoked and in whom data 
was available (n = 120), the mean number of years exposed 
to smoke was 18.9 (±0.74) years. The post-bronchodilator 
mean FEV1 at baseline was 1.7 (±0.07) liters and the mean 
initial FEV1 percentage of predicted was 51.3 (±2)%.
Follow-up
The mean (SEM; range) follow-up time was 41.7 (±2.6; 
range: 6 to 268) months. The number of spirometries was 2, 3, 
and 4 in 67%, 18% and 15% of patients, respectively (median 
of 2). During the follow-up 5.5% (n = 9) patients died.
Augmented versus non-augmented 
patients
Of the patients included in the analysis, 124 (76%) stated that 
they were receiving augmentation therapy (augmented group) 
and 40 patients (24%) declared that they were not receiving 
augmentation therapy (non-augmented group) at the time 
of the introductory questionnaire. In the augmented group, 
this treatment was initiated a mean of 69.6 (±6.7) months 
before the first FEV1 measurement available in the database. 
20 patients initiated this therapy after the first and before 
the second FEV1 result. The augmentation therapy used 
was predominantly weekly intravenous Prolastin® (Talecris 
Biotherapeutics), in 88% of the patients. Less commonly the 
patients received Aralast® (Baxter) (10% of the patients) and 
Zemaira® (CSL-Behring) (2% of the patients). Data were 
available in only 48 patients (39%).
The group treated with augmentation therapy was 
older (61.3 versus 56.1 years, P = 0.014) and had higher 
percentage of ex-smokers individuals (84.7 versus 62.5%, 
P  0.001). The presence of dyspnea, asthma and COPD 
(chronic obstructive pulmonary disease) was higher in the 
augmented group, leading to a higher use of inhaled bron-
chodilators and oxygen therapy (Table 1). The baseline 
post-bronchodilator FEV1 either in liters (1.41 versus 2.44 L, 
P  0.001) or percentage of predicted (43 versus 77%, 
P  0.001) was lower in the augmented group (Table 1). 
No difference between the groups were noted in the age 
at the time of diagnosis, gender, race, number of years 
of smoking, exposure to fumes or dust at work, history 
of bronchiectasis, hepatitis and cirrhosis, use of inhaled 
or systemic corticosteroids and theophylline. In addition 
no difference between the groups were found in duration 
of follow-up, number of spirometries, family history of 
AATD or emphysema, year when the first spirometry was 
performed, as well as in the 5-year mortality rate.
Overall change in FeV1 between the 
augmented versus the non-augmented 
group
When adjusted by age at baseline, sex, smoking status 
and baseline FEV1 % of predicted the augmented group 
had a mean increase in ∆FEV1 of 10.61 ± 21.4 mL/year. 
In comparison, the nonaugmented group had a mean 
decrease in ∆FEV1 of −36.96 ± 12.1 mL/year (P = 0.05), 
constituting an overall change in FEV1 (∆FEV1 in aug-
mented minus ∆FEV1 in the nonaugmented group) of 
47.6 mL/year between the two groups (Table 2). When International Journal of COPD 2009:4 446
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40 subjects (24%)
FEV1 < 50%
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(20%) 
FEV1 ≥ 50%
32 subjects 
(80%)
Figure 1 Flow diagram of study population analysis.
adding the 26 patients in whom the smoking history was 
initially missing, the difference between the augmented and 
non-augmented groups remained significant (∆FEV1 in the 
augmented group: 8.92 ± 19.95 mL/year versus ∆FEV1 in 
the non-augmented group: −34.96 ± 9.24 mL/year, overall 
FEV1 change of 43.88 mL/year, P = 0.046).
subgroup analysis
When patients were divided in 3 subgroups according 
to the initial FEV1 % of predicted (30%, 30% to 65% 
and 65%), a trend towards a beneficial effect of augmenta-
tion therapy was observed in the group with an initial FEV1 
between 30% to 65% (∆FEV1 augmented: 2.08 ± 24 mL/year International Journal of COPD 2009:4 447
Augmentation therapy in AATD Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
versus ∆FEV1 nonaugmented: –51.92 ± 18.1 mL/year; 
for an overall change in FEV1 of 54 mL/year, P = 0.07) 
(Figure 2). Of note is that the patients with FEV1 above 60% 
had higher rates of FEV1 decline if they received augmenta-
tion therapy (∆FEV1 augmented: −108.7 ± 17.3 mL/year 
versus ∆FEV1 non-augmented: −29.2 ± 15.29 mL/year; for 
an overall change in FEV1 of 79.46 mL/year, P  0.001) 
(Figure 2).
In the subset of patients with initial FEV1 % of predicted 
between 30% and 65%, one influential subject in the 
augmented group was identified using diagnostic statistics 
by PROC MIXED in SAS (SAS Institute). Omitting this 
subject the ∆FEV1 was 11.88 ± 23.96 mL/year in the aug-
mented group (n = 78) and −51.92 ± 18.14 mL/year in the 
non-augmented group, P = 0.034.
The analysis was repeated after adding 26 patients in 
whom the smoking history was initially missing. The inclusion 
of these patients did not modify the results for the 30% 
and 65% subgroups, however it made the difference, in 
the subgroup of patients with initial FEV1% between 30% 
and 65%, statistically significant (∆FEV1 in the augmented 
group (n = 89): 6.82 ± 24.07 mL/year versus ∆FEV1 in the 
Table 1 Comparative table of the patients receiving versus not receiving augmentation therapy 
Augmented group Non-augmented group P
n (%) 124 (76%) 40 (24%)
Age in yearsa 61.3 (0.7) 56.1 (1.9) 0.01
Age at diagnosis of AATDa 46.4 (0.8) 44.5 (1.8) 0.32
% Female gender 52.4% 50% 0.26
% White race 95.2 90% 0.58
% ex-smokers 84.7% 62.5% 0.001
% Current smokers 0% 5% 0.06
number of years of smokinga 19.4 (0.9) 17.3 (1.4) 0.2
exposure to dust or fumes at work 56.5% 45% 0.21
Dyspnea 91.9% 75% 0.004
Asthma 25% 10% 0.04
COPD (emphysema) 37.1% 15% 0.009
Bronchiectasis 12.1% 5% 0.25
Pneumonia 21% 12.5% 0.23
Pneumothorax 3.2% 2.5% 1
hepatitis 2.4% 7.5% 0.16
Cirrhosis 0% 5% 0.06
Fhx of AATD 63.7% 67.5% 0.66
Fhx of emphysema 40.3% 47.5% 0.42
Inhaled bronchodilator 86.3% 55% 0.001
Inhaled corticosteroid 59.7% 45% 0.1
Inhaled anticholinergics 6.5% 0% 0.2
Oral bronchodilators 11.3% 5% 0.24
systemic corticosteroids 7.3% 2.5% 0.3
Theophylline 10.5% 5% 0.3
Oxygen therapy 50.8% 12.5% 0.001
Baseline FeV1 (L/m)a 1.4 (0.1) 2.4 (0.2) 0.001
Baseline FeV1 (% of predicted)a 43 (2) 77 (5) 0.001
Duration of follow-up (months)a 43.6 (3.2) 35.7 (3.2) 0.19
number of spirometriesb 2 2 0.88
1st spirometry after 2004c 50% 57.5% 0.41
Deceased patients 8 (6.4%) 1 (2.5%) 0.46
Abbreviation: AATD, alpha-1 antitrypsin deficiency; FHx, family history.
Notes: aContinuous values are provided as mean (± SE); bMedian number of spirometries; cPercentage of patients in whom the first spirometry was performed after January 1, 2004.International Journal of COPD 2009:4 448
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non-augmented group: −49.44 ± 15.72 mL/year, for an over-
all change in FEV1 of 56.3 mL/year, P = 0.05).
When patients were divided in 2 subgroups (50% or 
50%), only the subgroup with an initial FEV1 50% of 
predicted benefited from augmentation treatment (∆FEV1 
augmented: 38.30 ± 33.7 mL/year versus ∆FEV1 non-
augmented: −86.73 ± 45.4 mL/year; for an overall change in 
FEV1 overall change in FEV1 of 125.03 mL/year, P = 0.03) 
(Figure 3). The inclusion of the patients with missing 
smoking history did not alter the results of this particular 
analysis.
When patients were divided by the smoking status, 
the beneficial effects of augmentation therapy were noted 
only in the group of patients classified as ex-smokers 
(∆FEV1 augmented: 24.24 ± 25.7 mL/year versus ∆FEV1 
non-augmented: −41.19 ± 22.5 mL/year; for an overall 
change in FEV1 of 65.4 mL/year, P = 0.05) (Figure 4). The 
patients that quit smoking did so 21.9 (±1.02) years before 
Table 2 Annual ∆FeV1 for the augmented and the non-augmented groups
Stratification Groups P-value
Augmented Non-augmented
n ∆FEV1 (mL/year) n ∆FEV1 (mL/year)
Initial FEV1
  30% pred 30 0.86 (17.63) 3 20.10 (31.06) 0.59
  30%–65% pred 79 2.08 (24.03) 10 −51.92 (18.14) 0.07
  65% pred  15 −108.7 (17.29) 27 −29.24 (15.29) 0.0006
Initial FEV1
  50% pred 88 38.30 (33.65) 8 −86.73 (45.37) 0.026
  50% pred 36 −49.46 (15.88) 32 −32.78 (13.15) 0.42
Smoking 
  non-smokers 19 −25.06 (49.53) 15 −38.43 (12.12) 0.79
  ex-smokers  105 24.24 (25.72) 23 −41.19 (22.47) 0.05
  Current smokers 0 – 2 – –
Total 124 10.61 (21.37) 40 −36.96 (12.13) 0.05
Notes: Results shown in the parentheses are standard errors of the estimated change in FeV1.   A positive ∆FeV1 represents an increase in FeV1, and a negative ∆FeV1 corresponds 
to a decrease in FeV1.
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Figure 2 ∆FEV1 (mL/year) in augmented and non-augmented patients by initial FeV1 % of predicted (65%, 30% to 65% and 30%). *P = 0.0006, **P = 0.07.International Journal of COPD 2009:4 449
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the inclusion in the study (range: 3.5 to 48.9 years). The 
inclusion of the patients with missing smoking history did 
not alter the results of this particular analysis.
Mortality
During the follow up, one patient died in the nonaugmented 
group and eight patients died in the augmented group. The 
5-year mortality rate in this group of patients was 2.5% 
and 4% for the nonaugmented and the augmented group, 
respectively (P = 0.581, by logistic regression). Of note is 
that patients in the augmented group were older, and more 
commonly had COPD with lower FEV1 and higher number 
of individuals required oxygen therapy.
Comparison with patients with 1 versus 
2 or more spirometries
Patients that had one FEV1 measurement (n = 296) had a 
higher mortality rate (9.8%) when compared to patients 
that had two or more FEV1 recorded in the database (4.1%) 
(P = 0.012), despite the shorter follow-up time (one third 
less) in the former group of patients. This suggest a possible 
“survivor effect” on the rate of FEV1 decline in patients who 
had 2 or more FEV1 measurements.
Discussion
In the group of patients with AATD studied, augmentation 
therapy improved lung function, manifested as an increase 
in the FEV1, when results were adjusted by age, gender, 
smoking status and baseline FEV1 percentage of predicted. 
The increase in FEV1 was only observed in ex-smokers and 
patients with FEV1  50% of predicted.
The FEV1 rate of decline in the non-augmented group is 
consistent with the one observed in previous observational 
studies.8,10 It is unclear why we found an unusual increase in 
FEV1 instead of a reduction in the FEV1 decline as reported 
in previous studies.5,15,16 Possible explanations include anti-
inflammatory effects of treatment with favorable effects over 
potential reversible processes such us bronchoconstriction 
and/or the use of different spirometry equipments. The 
first possible reason is supported by a higher incidence of 
asthma (25% versus 10%) and use of inhaled bronchodilators 
(86% versus 55%) in the group of patients receiving 
augmentation therapy. The use of different spirometry 
equipments, may have introduced variability in the results 
recorded. We cannot completely exclude the possibility of an 
increase in FEV1 associated with a submaximal expiratory 
effort (unfortunately peak flow was not recorded). To the best 
of our knowledge the centers in which the spirometries were 
performed followed the American Thoracic Society standards 
and the best effort was made to insure the best quality and 
reliability of spirometry results. It is interesting to note that 
in the Alpha-1-Antitrypsin Deficiency Registry Study Group, 
some patients had a positive FEV1 slope (in our case positive 
∆FEV1) when individual rates of FEV1 were shown.5
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Figure 3 ∆FEV1 (mL/year) in augmented and non-augmented patients by initial FeV1 % of predicted (50% and 50%).*P = 0.026.International Journal of COPD 2009:4 450
Tonelli et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
The increase in FEV1 in augmented patients was observed 
only in ex-smokers and patients with an initial FEV1 percentage 
of predicted 50%. Interestingly, augmented patients with 
an initial FEV1  65% of predicted had a significant larger 
FEV1 decline than nonaugmented patients, probably due to 
selection bias, as it is more likely to provide augmentation 
treatment to patients who have FEV1  65% and an 
accelerated FEV1 decline. Another possible explanation is 
based on the unusually low rate of FEV1 decline in patients 
with FEV1  65% who did not received augmentation 
therapy (∆FEV1−29.24 mL/year). This low value could have 
accentuated the differences in this subgroup of patients. A less 
likely possibility is a deleterious effect of augmentation 
therapy in AATD patients with FEV1  65%.
No difference in survival between the non-augmented and 
augmented group were observed when the 5-year mortality 
was adjusted for age, gender, smoking status, presence of 
COPD and baseline FEV1. As the overall sample is small and 
few patients died during the 3.5 year follow-up period, our 
study is underpowered to detect any difference in survival 
between the groups.
Few studies have compared the ∆FEV1 in patients 
receiving versus not receiving alpha-1 antitrypsin augmenta-
tion therapy. Seersholm et al compared the ∆FEV1 in AATD, 
among 97 Danish ex-smoker patients who did not received 
augmentation therapy, versus 198 German ex-smoker 
patients who received this therapy. The authors showed a 
significant slower rate of decline in patients treated with 
augmentation therapy (mean ∆FEV1 of 22 mL/year, P = 0.02). 
When stratified by the initial FEV1% of predicted, the authors 
showed a greater reduction in FEV1 decline among patients 
with initial FEV1 between 31% and 65% of predicted (mean 
overall change in FEV1 of 22 mL/year, P = 0.04).15
The Alpha-1-Antitrypsin Deficiency Registry Study 
Group included 927 AATD patients and found no differences 
in ∆FEV1 in patients receiving versus patients not receiving 
augmentation therapy (∆FEV1 4 mL/year, P = 0.4). However, 
a significant lower FEV1 decline was observed in patients 
receiving augmentation therapy who had an initial FEV1 
value of 35% to 49% predicted (overall change in FEV1 of 
27 mL/year, P = 0.03) or of 30% to 64% predicted (overall 
change in FEV1 of 18 mL/year, P = 0.03).5
Wencker et al analyzed the ∆FEV1 in 96 patients with 
severe before and after the institution of augmentation 
therapy. Overall, there was a significant lower decline 
in ∆FEV1 when patients received augmentation therapy 
in comparison with no treatment (∆FEV1 15 mL/year, 
P = 0.019). Patients with FEV1  30% before initiation of 
therapy showed a significant reduction of the FEV1 decline 
(overall change in FEV1 of 31.3 mL/year p  0.0001). No 
significant changes were noted in the group of patients with 
FEV1 30% to 65% or 65% of predicted.16
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Figure 4 ∆FEV1 (mL/year) in augmented and non-augmented patients by smoking status *P = 0.05.International Journal of COPD 2009:4 451
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Dirksen et al randomized 26 Danish and 30 Dutch patients 
with AATD to receive albumin versus alpha-1 antitrypsin 
augmentation therapy. No significant difference in the annual 
FEV1 change was noted between the groups (overall change in 
FEV1 of −19.8 mL/year, P = 0.25).17 The same authors recently 
reported the results of a randomized trial that included 
77 patients with AATD that received alpha-1 antitrypsin 
augmentation therapy or placebo. They explored the effect 
of augmentation treatment on computed tomography lung 
density. A trend suggestive of treatment benefit in the group 
receiving augmentation therapy was noted when change in 
lung density by computed tomography was used as outcome. 
No differences were observed in the mean annual FEV1 
decrease between the treatment and placebo groups.18
Selection bias at the time of the inclusion and “survivor 
effect” may help explain some of the discrepancies among the 
subgroup of patients that benefited the most when treated with 
alpha-1 antitrypsin augmentation therapy. When stratified by 
the initial FEV1 percentage of predicted the group of patients 
that benefited the most were the ones with FEV1 30% to 65%1,6 
or FEV1  30%.16 In our study, the subgroup of patients with 
an initial FEV1 35% to 65% of predicted showed a trend to 
benefit from augmentation therapy (P = 0.07). This difference 
became statistically significant after adding 26 patients in 
whom the smoking history was initially missing (P = 0.05) 
or when an influential subject in the augmented group 
was omitted from the analysis (P = 0.02). The studies by 
Seersholm et al and Alpha-1-Antitrypsin Deficiency Registry 
Study Group observed a beneficial effect of augmentation 
therapy in the subgroup of patients with an initial FEV1 30% 
to 65% of predicted.5,15
The majority of patients included in the previous studies 
were ex-smokers, especially in the group of patients that 
received augmentation therapy.5 Similarly in our study, 78% 
of the patients were ex-smokers and this percentage increase 
to 85% when only considering the augmented patients. Only 
two patients were current smokers at the time of inclusion. 
A significant overall change in FEV1 was only noted in the 
group of patients that were ex-smokers. This difference is not 
attributable to a reduction in the rate of FEV1 decline due to 
discontinuation of tobacco products as ex-smoker patients 
quit smoking an average of 21.9 years before the inclusion 
in the study (all ex-smoker patients quit smoking at least 
3 years before their inclusion).
Non-smokers had a non significant difference in the rate 
of FEV1 decline, probably due to a reduced effect of therapy, 
in patients with slower FEV1 decline, or smaller sample size. 
Observational studies have shown no significant difference 
in the rate of FEV1 decline when ex-smokers were compared 
with non-smokers.8
The majority of patients included in our study received 
augmentation therapy (76%). Reasons for not receiving 
therapy included: 1) not recommended by physician (n = 10), 
2) recent diagnosis, 3) waiting to begin therapy, 4) finan-
cial reasons and 5) personal desire. The mean FEV1 % of 
predicted for the patients who did not received therapy by 
physician recommendation was 95 (±7)%, meanwhile for the 
rest of the patients in the nonaugmented group the mean (SE) 
FEV1 % of predicted was 48 (±2)%, (P  0.001).
A similar percentage of AATD patients treated with 
augmentation therapy (70%) was reported by the Alpha-1-
Antitrypsin Deficiency Registry. The main reasons for not 
receiving therapy in the registry were 1) not indicated or 
recommended by physician, 2) high cost, 3) receipt or antici-
pation of a lung transplant and 4) medical contraindication. 
Patients who did not receive augmentation therapy had higher 
FEV1, less pulmonary symptoms, lower family income and 
were less likely to have insurance coverage (5).
Limitations of our study included 1) observational 
non-randomized study; 2) a possible selection bias, as only 
patients who had all the variables of interest recorded and 
who had two spirometries at least 6 months apart were 
included in the analysis (patients had a higher mortality 
rate if they only had one FEV1 measurement in comparison 
with two or more, leading to an underestimation of the rate 
of FEV1 decline, the so called “healthy survivor effect”); 
3) spirometries were performed in different centers that used 
diverse equipments; 4) patients were divided in augmented 
and non-augmented group at the time of the inclusion in the 
study (some patients may have started or stopped therapy 
afterwards); 5) the criteria for starting treatment and com-
pliance with therapy were not recorded, 6) the length of 
follow-up was relatively short (3.5 years), 7) other risk 
factors that may influence the rate of FEV1 decline, such us 
bronchodilator response and respiratory exacerbation rates 
were not investigated.10,12,19–22
In spite of the previous limitations, our study has a different 
research design, and the analysis of the data still supports the 
findings of previous studies, that showed an improvement 
in lung function in AATD patients receiving augmentation 
therapy. This study demonstrated that ex-smokers with 
FEV1  50% benefited the most from alpha-1 antitrypsin 
augmentation therapy. In addition it provides “everyday 
practice” information about the characteristics of patients 
with AATD that received versus the ones that did not receive 
alpha-1 antitrypsin augmentation therapy.International Journal of COPD 2009:4
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-copd-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
452
Tonelli et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Conclusion
Augmentation therapy improves lung function in patients 
with AATD when adjusted by age, gender, smoking status 
and baseline FEV1 % of predicted. The beneficial effects 
were noted in ex-smoker patients with FEV1 below 50% of 
predicted.
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